Serum Mucin-Associated Antigen Levels of Cystic Fibrosis Patients Are Related to Their Ages and Clinical Statuses

Frates, Ralph C.; Fink, Robert; Chernick, Milica S.; Brooks, John O.; Ginsburg, Victor; Roberts, David D.

doi:10.1203/00006450-198901000-00013

Cited by 10 publications

(13 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First, serum mucin from a single CF patient most resembled human lung mucin with respect to carbohydrate and amino acid composition (5). Second, serum sialyl Lea antigen levels correlated with measures of lung disease in two studies of groups of CF patients (7,8). Third, of 39 CF patients in the present study, 22 had some evidence of lung disease when their blood was drawn.…”

Section: Discussionmentioning

confidence: 86%

“…In a previous study of 89 CF patients (7), serum mucin levels significantly increased with age and degree of sickness. No relationship between age and serum mucin levels was noted in neonates and young children.…”

Section: Discussionmentioning

confidence: 99%

“…Unfortunately, the CF patients' Lewis blood group types are unknown, but there is no obvious selection bias favoring such patients. Moreover, our own previous studies have demonstrated large elevations of sialyl Lea antigen among adult CF patients whose blood type is Leb (7).…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, absolute levels of antigen cannot be directly correlated with disease status in individual patients. By population studies and longitudinal studies of individual patients, however, antigen levels have been correlated with recurrence or progression of tumors in patients with mucin-secreting adenocarcinomas and with age, clinical status, and pulmonary status of patients with CF (7,8).…”

mentioning

confidence: 99%

“…Sialyl Lea antigen may be used as a tumor marker (6). Sialyl Lea antigen (or mucin) levels in serum are related to the age, clinical status, and pulmonary status of CF patients (7,8). The purpose of the present study was to compare serum antigen levels of healthy newborns or infants and young children who had lung diseases (e.g.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Infants and Young Children with Cystic Fibrosis Have High Levels of Serum Sialyl Lewisa Antigen

Frates¹,

Scott²,

Hammond

et al. 1995

Pediatr Res

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 86%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Infants and Young Children with Cystic Fibrosis Have High Levels of Serum Sialyl Lewisa Antigen

Frates¹,

Scott²,

Hammond

et al. 1995

Pediatr Res

Self Cite

View full text Add to dashboard Cite

Tumor markers CA 19‐9 and CA 195 are also useful as markers for cystic fibrosis

Wu¹,

Olson²,

Kay³

1992

Clinical Laboratory Analysis

View full text Add to dashboard Cite

When monoclonal kits are used we can no longer detect highly elevated serum concentrations of carcinoembryonic antigen in cystic fibrosis (CF) patients as we could earlier (Pediatr Res 10:223-236, 1975). Instead, we find increased concentrations of CA 19-9 or CA 195 in the CF sera. The serum levels of CA 19-9 not only reflect the pulmonary condition of CF patients but also respond well to antibiotic therapy. Several lines of evidence suggest that the elevated serum concentration of CA 19-9 is derived from sputum and corresponds with the amount of sputum in the lung. Correlations between CA 19-9 and CA 195 in random and serial specimens from both patients with CF and patients with pancreatic carcinoma suggest that all sera contain heterogeneous, Lewis blood group-related epitopes and the proportions of various epitopes are different among individual patients. When monitored on multiple tumor markers, the pattern of CF is different from that of pancreatic carcinoma although both usually show elevated CA 19-9. Our study indicates that both CA 19-9 and CA 195 can be used as sensitive markers for the early detection of exacerbation in CF patients.

show abstract

Chromatographic characterization of CA 19‐9 molecules from cystic fibrosis and pancreatic carcinoma

Wu¹,

Chang²

1992

Clinical Laboratory Analysis

View full text Add to dashboard Cite

We have compared the size, the binding to Concanavalin A (Con A), and the affinity for monoclonal antibody 1116NS-199 (Mab 19-9) among CA 19-9 molecules from sera of cystic fibrosis (CF) and pancreatic carcinoma patients and from sputum extracts. CA 19-9 molecules of two different sizes were found in all types of specimens by Sepharose 4B chromatography. While the smaller CA 19-9 molecule was predominant in CF patient sera, the larger molecule was associated with most of the sera from patients with pancreatic carcinoma. The majority of the sputum extracts contained the larger CA 19-9 molecule. All CA 19-9 molecules studied by Con A chromatography did not appear to bind to Con A, and almost 100% were found in the nonreactive fraction. The CA 19-9 molecules from sera of either CF or pancreatic carcinoma patients exhibited variable affinities for Mab 19-9, some approaching that of the standard curve but many also having lower affinities. The lowest affinity was displayed by CA 19-9 molecules from the sputum extract. It appears that development of more specific assays for CF and for carcinoma is possible if the correct CA 19-9 molecule is selected for antibody preparation and for use as standards.

show abstract

Serum Mucin-Associated Antigen Levels of Cystic Fibrosis Patients Are Related to Their Ages and Clinical Statuses

Cited by 10 publications

References 45 publications

Infants and Young Children with Cystic Fibrosis Have High Levels of Serum Sialyl Lewisa Antigen

Infants and Young Children with Cystic Fibrosis Have High Levels of Serum Sialyl Lewisa Antigen

Tumor markers CA 19‐9 and CA 195 are also useful as markers for cystic fibrosis

Chromatographic characterization of CA 19‐9 molecules from cystic fibrosis and pancreatic carcinoma

Contact Info

Product

Resources

About